Comprehensive approach to the treatment of inverse psoriasis in patients with type 2 diabetes mellitus

Psoriasis is a chronic multifactorial inflammatory disease that can manifest itself in various clinical forms. In addition to smooth skin, this disease can affect folds, joints (psoriatic arthritis) and nails. Purpose of the study. Due to the variety of clinical forms, severity of psoriasis and concomitant diseases that we can observe in patients, universal treatment regimens have not yet been developed. Therefore, the purpose of the study is to use an interdisciplinary complex approach to the treatment of psoriasis in patients with concomitant carbohydrate metabolism disorders. Materials and methods. This article considers 2 clinical cases of inverse psoriasis occurring against the background of concomitant diseases (diabetes mellitus type 2, hepatitis C) using individual treatment regimens. Results and their discussion. Basic treatment of psoriasis includes the use of both systemic and topical drugs. In the treatment of inverse psoriasis in a patient with type 2 diabetes mellitus, together with systemic treatment with immunosuppressive drugs, we used therapy aimed at normalizing glycemia. Topical combined topical glucocorticosteroids in the form of a cream, as well as aniline dyes, were used externally. In the treatment of inverse psoriasis in a patient with type 2 diabetes mellitus in combination with hepatitis C, together with systemic treatment with hepatoprotectors, monoclonal antibody preparations are used, as well as hypoglycemic drugs. Topical combined topical glucocorticosteroids in the form of an ointment, aniline dyes, and aqueous solutions of antiseptics were used externally. In the presented clinical cases, patients are under the supervision of doctors of related specialties for a comprehensive approach to the treatment of patients with comorbid conditions. Conclusions. To determine the most appropriate tactics for the treatment of inverse psoriasis in patients with concomitant pathology, an interdisciplinary approach to patient management is required.

psoriasis, inverse psoriasis, hepatitis C, type 2 diabetes mellitus, cytostatics, hepatoprotectors, biological therapy, topical corticosteroids, clinical case

1. Kruglova L.S., Bakulev A.L., Korotaeva T.V., Lila A.M., Pereverzeva N.O. Psoriasis. Moscow. GEOTAR-Media., 2022; 328P. (In Russ.)@@ Круглова Л.С., Бакулев А.Л., Коротаева Т.В., Лила А.М., Переверзева Н.О. Псориаз. ГЭОТАР-Медиа. 2022; 328с.

2. Kruglova L.S., Korotaeva T.V. Program of medical and social support for patients with psoriasis and (or) psoriatic arthritis who are indicated for therapy with genetically engineered biological drugs in real clinical practice. Scientific and Practical Rheumatology. 2020;58(5):495-502. (In Russ.) doi: 10.47360/1995-4484-2020-495-502.@@ Круглова Л.С., Коротаева Т.В. Программа медико-социального сопровождения пациентов с псориазом и (или) псориатическим артритом, которым показана терапия генно-инженерными биологическими препаратами в условиях реальной клинической практики. Научно-практическая ревматология. 2020;58(5):495-502. doi: 10.47360/1995-4484-2020-495-502.

3. Kruglova L.S., Rudneva N.S., Bakulev A.L., Khotko A.A. Medical alphabet - Inverse psoriasis and psoriasis of “difficult” localizations: the effectiveness of netakimab. Medical alphabet. 2022;1(27):14-20. (In Russ.) doi: 10.33667/2078-5631-2022-27-14-20.@@ Круглова Л.С., Руднева Н.С., Бакулев А.Л., Хотко А.А. Медицинский алфавит-Инверсный псориаз и псориаз «трудных» локализаций: эффективность нетакимаба. Медицинский алфавит. 2022;27:14-20. doi: 10.33667/2078-5631-2022-27-14-20.

4. Shafieva I.A., Bulgakova S.V., Kurmaev D.P., Treneva E.V. Use of tofacitinib in psoriatic arthritis (literature review). Medical Council. 2024;(12):114-122. (In Russ.) doi: 10.21518/ms2024-230.@@ Шафиева И.А., Булгакова С.В., Курмаев Д.П., Тренева Е.В. Применение тофацитиниба при псориатическом артрите (обзор литературы). Медицинский Совет. 2024;(12):114-122. doi: 10.21518/ms2024-230.

5. Arsenyeva A.A., Migacheva N.B., Lyamin A.V., Kurmaev D.P. Immunobiological therapy of psoriasis. Current state of the problem (Review of literature).Russian Allergological Journal. 2025;21(4). (In Russ.) doi: 10.36691/RJA16974.@@ Арсеньева А.А., Мигачёва Н.Б., Лямин А.В., Курмаев Д.П. Иммунобиологическая терапия псориаза. Современное состояние проблемы (Обзор литературы). Российский Аллергологический Журнал. 2025;21(4). doi: 10.36691/RJA16974.

6. Bakulev A.L., Shagova Yu.V., Kozlova I.V. Psoriasis as a systemic pathology. Saratov Scientific Medical Journal. 2008;1:13-19. (in Russ.) ISSN 1995-0039 Print, ISSN 2076-2518 Online.@@ Бакулев А.Л., Шагова Ю.В., Козлова И.В. Псориаз как системная патология. Саратовский научно-медицинский журнал. 2008;1:13-19. ISSN 1995-0039 Print, ISSN 2076-2518 Online.

7. Lykova S.G., Morzhanaeva M.A., Nemchaninova O.B., Svechnikova E.V. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Clinical dermatology and venereology. 2020;19(2):214-222. (In Russ.) doi: 10.17116/klinderma202019021214.@@ Лыкова С.Г., Моржанаева М.А., Немчанинова О.Б., Свечникова Е.В. Псориаз у пациентов с метаболическим синдромом: клинические аспекты проблемы. Клиническая дерматология и венерология. 2020;19(2):214-222. doi: 10.17116/klinderma202019021214.

8. Rodríguez-Zúñiga M.J.M., García-Perdomo H.A. Systematic Review and Meta-Analysis of the Association Between Psoriasis and Metabolic Syndrome. J Am Acad Dermatol. 2017;77(4):657-666. doi: 10.1016/j.jaad.2017.04.1133.

9. Udalova I.V., Gerasimova D.D., Gulyants N.M., Okhlopkov V.A. MEDSI Bulletin. 2024;2(35):69-74. (In Russ.) doi: 10.33029/2949-4613-2023-11-2-8-14.@@ Удалова И.В., Герасимова Д.Д., Гульянц Н.М., Охлопков В.А. Вестник МЕДСИ. 2024;2(35):69-74. doi: 10.33029/2949-4613-2023-11-2-8-14.

10. Armstrong A.W., Schupp C., Bebo B. Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology. 2012;225: 121-126. doi: 10.1159/000342180.

11. Gelfand J.M., Troxel A.B., Lewis J.D. et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143:1493-1499. doi: 10.1001/archderm.143.12.1493.

12. Kochergin N., Smirnova L., Potekaev N., Bilalova U. Psoriasis: comorbidities and comedications. Doctor. 2009;5:15-20. (In Russ.)@@ Кочергин Н., Смирнова Л., Потекаев Н., Билалова У. Псориаз: коморбидности и комедикации. Врач. 2009;5:15-20.

13. Röcken M., Schaller M., Sattler E., Burgdorf W. Atlas of Dermatology. MEDpress-inform. 2012;174. (In Russ.)@@ Рёкен М., Шаллер М., Заттлер Э., Бургдорф В. Атлас по дерматологии. МЕДпресс-информ. 2012;174.

14. Shapiro J., Cohen A.D., David M., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J AmAcad Dermatol. 2007;56(4): 629-634. DOI: 10.1016/j.jaad.2006.09.017.

15. Russian Society of Dermatovenerologists and Cosmetologists Federal Clinical Guidelines for the Management of Patients with Psoriasis. 2023. (In Russ.)@@ Российское общество дерматовенерологов и косметологов Федеральные клинические рекомендации по ведению больных с псориазом, 2023 г.

16. Bakulev A.L., Kravchenya S.S. Use of hepatoprotectors in psoriasis: comparative clinical, laboratory and ultrasonographic evaluation of effectiveness. Bulletin of Dermatology and Venereology. 2010;1:112-117. (In Russ.) doi: 10.25208/vdv.1005.@@ Бакулев А.Л., Кравченя С.С. Применение гепатопротекторов при псориазе: сравнительная клинико-лабораторная и ультрасонографическая оценка эффективности. Вестник дерматологии и венерологии. 2010;1:112-117. doi: 10.25208/vdv.1005.